The company will not receive any proceeds from the sale of shares of common stock by the selling stockholders.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026
- Lexaria Bioscience achieves primary endpoint in Phase 1b study GLP-1-H24-4
- Lexaria Bioscience Secures $3.5 Million in Direct Offering to Boost R&D
- Lexaria Bioscience prices 2.66M share at the market offering at $1.315
- Lexaria Extends Agreement to Advance Drug Delivery Technology Evaluation